Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience, Inc. (VIGL) is a pioneering biopharmaceutical company dedicated to developing microglia-focused therapeutics. These specialized treatments aim to treat both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Vigil Neuroscience leverages modern neuroscience drug development tools to create precision-based therapies that significantly improve the quality of life for patients and their families.
One of the company's key initiatives is the clinical development of iluzanebart, which is currently in a Phase 2 Proof of Concept (PoC) trial named IGNITE. This is the first-ever interventional trial targeting Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) patients, marking a critical advancement in the treatment landscape for this rare disease. In addition, the company is working on VG-3927, an orally available small molecule TREM2 agonist designed to treat more common neurodegenerative diseases associated with microglial dysfunction.
Vigil Neuroscience has also made notable strides in community engagement and support. Their comprehensive patient support initiatives include the ALSPAware program, which offers no-cost genetic testing and counseling. This program aims to reduce the barriers to accurate diagnosis and enable better disease management for ALSP patients.
Recent research presented by the company has revealed significant findings on the diagnostic challenges faced by the ALSP community. For instance, a retrospective analysis disclosed that only 24.7 percent of ALSP patients received an accurate initial diagnosis, with many being misdiagnosed with multiple sclerosis (MS) due to similar early symptoms. Vigil Neuroscience's ongoing research aims to provide better diagnostic tools and treatment options, thereby improving the overall patient journey.
Additionally, Vigil Neuroscience has been actively presenting its latest findings and achievements at various conferences. Recent presentations have highlighted the potential of VG-3927 to treat neurodegenerative diseases like Alzheimer's Disease (AD), showcasing its neuroprotective profile and ability to favorably modulate microglia activation.
As Vigil Neuroscience continues to advance its clinical programs and expand its therapeutic pipeline, it remains committed to delivering innovative solutions that address the unmet needs of patients suffering from neurodegenerative diseases.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two major investor conferences. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 4:45 p.m. ET and the Jefferies London Healthcare Conference on November 20th at 8:30 a.m. GMT. Both presentations will be in a fireside chat format. The webcasts will be accessible through the company's website's Investors section and will remain available for approximately 90 days after the presentations.
Vigil Neuroscience (NASDAQ: VIGL) reported Q3 2024 financial results with a net loss of $19.3 million, compared to $20.5 million in Q3 2023. The company ended Q3 with $111.3 million in cash and equivalents, expecting to fund operations into 2026. R&D expenses decreased to $13.8 million from $15.4 million year-over-year, while G&A expenses remained stable at $6.9 million.
Key developments include planned final analysis of the IGNITE Phase 2 trial for iluzanebart in ALSP in H1 2025, and Phase 1 clinical data for VG-3927 in Alzheimer's Disease expected in Q1 2025. The company also reported new ALSP prevalence estimates of approximately 19,000 cases in the U.S. and 29,000 in EU/UK combined.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on developing microglia-based treatments for neurodegenerative diseases, has announced its participation in the Guggenheim Healthcare Innovation Conference. The company's management will engage in a fireside chat on November 11, 2024, at 10:30 a.m. ET. A live webcast will be available for registration and can be accessed through the company's website under the Investors section. The recorded session will remain accessible for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL) announced that the FDA has removed the partial clinical hold on its Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease. The decision was based on non-clinical and clinical data from the ongoing trial. Interim data from July 2024 showed a favorable safety and tolerability profile, predictable pharmacokinetics supporting once-daily dosing, and proof of target engagement. The company has initiated dosing in Alzheimer's patients, including those with TREM2 variants. Vigil plans to report complete Phase 1 data, including results from the AD patient cohort, in Q1 2025.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in the Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 9:45 a.m. ET.
Interested parties can register for the live webcast through a provided link. The webcast will also be accessible on Vigil Neuroscience's website in the 'Investors' section under 'Events & Presentations'. An archived version of the webcast will remain available for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: A fireside chat scheduled for Thursday, September 5th at 2:35 p.m. ET.
2. H.C. Wainwright 26th Annual Global Investment Conference: Another fireside chat set for Tuesday, September 10th at 10:30 a.m. ET.
Both events will feature live webcasts available on the company's website under the 'Events & Presentations' page in the 'Investors' section. These webcasts will remain accessible for approximately 90 days after the presentations.
Vigil Neuroscience (VIGL) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. A $40 million strategic investment from Sanofi, extending cash runway into 2026.
2. Updated clinical development strategy for iluzanebart, pursuing a potential accelerated approval pathway in ALSP.
3. Interim data from VG-3927 Phase 1 trial supporting continued development for Alzheimer's disease.
4. Q2 2024 financials: $86.7 million in cash and equivalents, $15.5 million in R&D expenses, and $21.2 million net loss.
5. Plans to report final analysis from IGNITE clinical trial in H1 2025 and complete Phase 1 data for VG-3927 in Q1 2025.
Vigil Neuroscience (Nasdaq: VIGL) highlights a new publication in Neurology Genetics on the prevalence of CSF1R gene variants associated with adult-onset leukoencephalopathy with axonal-spheroids and pigmented glia (ALSP). The study suggests ALSP is underreported, with an estimated prevalence of 281 per 1 million in the UK population. This translates to approximately 19,000 cases in the U.S. and 29,000 in the EU and UK, significantly higher than previous estimates. The research indicates there may be over 2 million carriers worldwide. ALSP, a rare neurodegenerative disorder caused by CSF1R mutations, is often misdiagnosed and requires genetic testing for confirmation. This new data emphasizes the need for increased genetic screening and awareness to improve diagnosis and support for ALSP patients.
Vigil Neuroscience (NASDAQ: VIGL) presented data on its small molecule TREM2 agonist program at the 2024 Alzheimer's Association International Conference. The company shared clinical data from single ascending dose (SAD) cohorts in its ongoing Phase 1 trial of VG-3927, demonstrating proof-of-pharmacology with a robust decrease of sTREM2 in the CSF.
Key highlights include:
- In vivo data showing selective activation of downstream function leading to microglial amyloid-beta phagocytosis
- Acute modulation of AD pathophysiology comparable to an approved therapeutic
- In vitro data demonstrating preferential activity on cellular TREM2
- Phase 1 trial design details for VG-3927 in healthy volunteers
- Pharmacological and functional characterization of VG-3927 as a TREM2-specific, highly potent molecule
Vigil believes VG-3927 has the potential to offer a differentiated approach to treating Alzheimer's disease.
Vigil Neuroscience (Nasdaq: VIGL) has announced promising interim data from its ongoing Phase 1 clinical trial of VG-3927, a potential once-daily oral therapy for Alzheimer's disease (AD). The trial, which has enrolled 80 healthy volunteers, demonstrated a favorable safety and tolerability profile, with all adverse events being mild or moderate and resolving without intervention. Key findings include:
1. VG-3927 achieved a robust decrease in sTREM2 in cerebrospinal fluid, indicating clinical proof-of-target engagement.
2. The drug showed a predictable pharmacokinetic profile supporting once-daily dosing.
3. An increase in osteopontin/SPP1, a biomarker associated with neuroprotective microglia, was observed after repeat dosing.
Vigil plans to report complete Phase 1 data, including results from an AD patient cohort, in Q1 2025. The company will present new preclinical and clinical data at the upcoming 2024 Alzheimer's Association International Conference.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
What is the primary focus of Vigil Neuroscience, Inc.?
What is iluzanebart?
What is VG-3927?
What is the ALSPAware program?
What recent findings has Vigil Neuroscience presented?
How does Vigil Neuroscience contribute to the neurodegenerative disease community?
What is the IGNITE trial?
Why is microglia important in neurodegenerative diseases?
What challenges do ALSP patients face in terms of diagnosis?
Who can I contact for investor and media inquiries?
